Economic and Financial Impacts of Cancer

SEP 10, 2026 · JOURNAL ARTICLE

Modernizing Surrogate Decision-Making to Reflect the Complexity of Cancer Care

JAMA Oncology

This is a viewpoint piece proposing a framework for surrogate decision-making in cancer care; it presents expert perspective and normative guidance rather than empirical evidence of efficacy or outcomes.

SEP 10, 2026 · JOURNAL ARTICLE

Risk Adjustment in the Medicare Advantage Population Using Encounter Data

Health Services Research

A methodological study replicating and stress-testing an existing risk model using observational data; findings suggest potential recalibration needs but lack a prospective design, randomization, or definitive clinical outcome to warrant stronger classification.

SEP 10, 2026 · JOURNAL ARTICLE

Patterns of Health Care Spending in Prostate Cancer

JAMA Network Open

A descriptive economic analysis of spending patterns using administrative data; documents trends but lacks comparative design, causal inference, or clinical outcomes to support practice change.

SEP 9, 2026 · JOURNAL ARTICLE

The high price of innovation: addressing financial toxicity and healthcare inequity in gynecological malignancies

Frontiers in Oncology

A narrative review synthesizing evidence on financial toxicity in gynecological oncology and policy recommendations for equitable access to innovation, grounded in published literature but without new empirical data.

SEP 9, 2026 · JOURNAL ARTICLE

Physicians’ Perspectives on Access to Innovative Oncology Therapies: A Cross-Sectional Survey in Bulgaria

Healthcare

A descriptive cross-sectional survey of physician perceptions with no control group, experimental intervention, or clinical outcome; generates hypotheses about access barriers rather than testing them.

SEP 4, 2026 · JOURNAL ARTICLE

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Journal of Cancer Survivorship

Mixed-methods validation study of two screening tools in a single centre with small qualitative sample (n=20), generating hypothesis that multi-measure approach may be needed rather than establishing superior measurement strategy.

AUG 18, 2026 · JOURNAL ARTICLE

Institutional and national Budget impact of alternative pembrolizumab dosing in non-small cell lung cancer: a real-world Pharmacoeconomic Analysis

Expert Review of Pharmacoeconomics & Outcomes Research

A single-center retrospective pharmacoeconomic model with simulated dosing strategy and no clinical outcome data; findings require prospective validation before implementation.

AUG 13, 2026 · JOURNAL ARTICLE

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap

Haematologica

A White Paper outlining strategic recommendations and a roadmap for international registry collaboration in lymphoma, not reporting original research findings or clinical trial data.